Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained remissions in these patients. However, CAR T cells can result in significant toxicities. Preinfusion disease burden is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wudhikarn, Kitsada, Tomas, Ana Alarcon, Flynn, Jessica R., Devlin, Sean M., Brower, Jamie, Bachanova, Veronika, Nastoupil, Loretta J., McGuirk, Joseph P., Maziarz, Richard T., Oluwole, Olalekan O., Schuster, Stephen J., Porter, David L., Bishop, Michael R., Riedell, Peter A., Perales, Miguel-Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338201/
https://www.ncbi.nlm.nih.gov/pubmed/36355838
http://dx.doi.org/10.1182/bloodadvances.2022008294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338201/
https://www.ncbi.nlm.nih.gov/pubmed/36355838
http://dx.doi.org/10.1182/bloodadvances.2022008294

Ejemplares similares